Gamez-Cenzano C.,Institute Of Diagnostic Per La Imatge Idi |
Pino-Sorroche F.,Institute Catala dOncologia ICO
PET Clinics | Year: 2014
There is a growing interest in using quantification in FDG-PET/CT in oncology, especially for evaluating response to therapy. Complex full quantitative procedures with blood sampling and dynamic scanning have been clinically replaced by the use of standardized uptake value measurements that provide an index of regional tracer uptake normalized to the administered dose of FDG. Some approaches have been proposed for assessing quantitative metabolic response, such as EORTC and PERCIST criteria in solid tumors. When using standardized uptake value in clinical routine and multicenter trials, standardization of protocols and quality control procedures of instrumentation is required. © 2014 Elsevier Inc. All rights reserved.
Garzon-Rodriguez C.,Institute Catala dOncologia ICO
Medicina Paliativa | Year: 2015
Proper health education is essential for the successful management and treatment of pain. In recent years, there has been a clarification of both the clinical features and diagnostic criteria of breakthrough cancer pain (BTcP), producing a new generation of drugs (fentanyl) with transmucosal absorption. Multiple clinical trials have been conducted on the safety and efficacy of these fentanyl preparations for the treatment of BTcP. The common denominator in most of these studies is the lack of relationship between the effective dose of fentanyl that controls pain exacerbations and the around-the-clock opioid dose, and therefore individualized titration should always be performed. Titration of fentanyl in any of its forms (transmucosal nasal/oral) therefore requires close monitoring of analgesia and adverse effects with each dose administered. Health education in patients and their families on the use of rapid-release opioids is a key aspect of their success. In this article, we describe the health education tools that have been developed by the palliative care service of the Catalan Institut of Oncology to facilitate the understanding of the use and titration of these drugs. © 2015 Sociedad Española de Cuidados Paliativos.
Gornick M.C.,University of Michigan |
Rennert G.,Technion - Israel Institute of Technology |
Moreno V.,Technion - Israel Institute of Technology |
Moreno V.,Institute Catala dOncologia ICO |
Gruber S.B.,University of Michigan
British Journal of Cancer | Year: 2011
Background: Genes of the adiponectin pathway are interesting candidates for colorectal cancer risk based on the potential association between colorectal cancer and obesity. However, variants of the adiponectin gene (ADIPOQ) have been demonstrated to be inconsistently associated with risk of colorectal cancer. Methods: The current study attempted to evaluate these findings by examining several single nucleotide polymorphisms (SNPs) that were previously genotyped as part of a genome-wide association study in the ADIPOQ gene. Genotyping was also performed for a previously reported risk variant, rs266729, in 1062 individuals with a diagnosis of colorectal cancer and 1062 controls matched on age, gender and ethnicity (Jewish or not Jewish) as part of a population-based case-control study in Israel. Results: No evidence was found for an association between ADIPOQ and risk of colorectal cancer. The single nucleotide variant previously associated with decreased risk of colorectal cancer, rs266729, revealed an adjusted odds ratio of 1.04; 95% confidence interval, 0.88-1.23. Conclusion: The SNP, rs266729, was not strongly associated with colorectal cancer in patients of Ashkenazi Jewish descent or other ethnic groups in Israel. © 2011 Cancer Research UK.
Reggiori G.,Istituto Clinico Humanitas |
Puxeu Vaque J.,Institute Catala dOncologia ICO |
Calle C.,Kantonsspital |
Scorsetti M.,Istituto Clinico Humanitas |
And 2 more authors.
Medical Physics | Year: 2012
Purpose: Pretreatment quality assurance data from four centers, members of the European TrueBeam council were analyzed with different verification devices to assess reliability of flattening filter free beam delivery for intensity modulated radiotherapy (IMRT) and RapidArc (RA) techniques. Methods: TrueBeam® (Varian Medical System) is a new linear accelerator designed for delivering flattened, as well as flattening filter free beams. Pretreatment dosimetric validation of plan delivery was performed with different verification devices and responses to high dose rates were tested. Treatment planning was done in Eclipse planning system (PRO 8.9, AAA 8.9). evaluation was performed with (dose difference) 3 and (distance to agreement) 3 mm scoring the gamma agreement index (GAI, of field area passing the test). Two hundred and twenty-four patients with 1-6 lesions in various anatomical regions and dose per fraction ranging from 1.8 Gy to 25 Gy were included in the study; 88 were treated with 6 MV flattening filter free (X6FFF) beam energy and 136 with 10 MV flattening filter free (X10FFF) beam. Gafchromic films in solid water, delta4, arccheck, and matrixx phantom were used to verify the dose distributions. Additionally, point measurements were performed using a PinPoint chamber and a Farmer chamber. Results: Dose calculation as well as dose delivery was equally accurate for IMRT and RA delivery (IMRT: GAI 99.3 (±1.1); RA: GAI 98.8 (±1.1) as well as for the two beams evaluated (X6FFF: GAI 99.1 (±1.0); X10FFF: GAI 98.8 (±1.2). Only small differences were found for the four verification devices. A point dose verification was performed on 52 cases, obtaining a dose deviation of 0.34. The GAI variations with number of monitor units were statistically significant. Conclusions: The TrueBeam FFF modality, analyzed with a variety of verification devices and planned with Eclipse planning system is dosimetrically accurate (within the specified limits 3 mm/3) for both X6FFF and X10FFF beam energy. © 2012 American Association of Physicists in Medicine.
Gros A.,U.S. National Institutes of Health |
Guedan S.,Institute Catala dOncologia ICO
Open Gene Therapy Journal | Year: 2010
Adenovirus release is not triggered until late times after viral infection when the adenovirus death protein (ADP) accumulates to induce viral egress. Thus the natural rate of adenovirus release may hinder the spread of oncolytic adenoviruses. Several experimental approaches have provided evidence indicating that promoting adenovirus release can be used to enhance their therapeutic potential. This review briefly summarizes what is known about the mechanism of adenovirus release and describes three different strategies, ADP overexpression, apoptosis induction, and bioselection, which can be used to enhance adenovirus release.Finally we will discuss some of the future perspectives that will contribute to the better use of progeny release for the improvement of the antitumor activity of oncolytic adenoviruses. © Gros and Guedan.; Licensee Bentham Open.